BridgeBio Oncology Therapeutics, Inc. filed its Form 10-Q with the Securities and Exchange Commission on November 10, 2026, covering the quarterly period ended September 30, 2026.

Key Highlights

  • Net loss for Q3 2026: $34,176 thousand for the three months ended September 30, 2026, compared to $44,757 thousand for the same period in 2025, according to the filing.
  • Nine-month net loss: $132,736 thousand for the nine months ended September 30, 2026, versus $95,247 thousand for the same period in 2025.
  • Total assets: $346,224 thousand as of September 30, 2026, down from $448,381 thousand as of December 31, 2025.
  • Cash and cash equivalents: $76,479 thousand as of September 30, 2026, compared to $373,687 thousand at December 31, 2025.
  • Research and development expenses: $29,593 thousand for Q3 2026, and $118,620 thousand for the nine months ended September 30, 2026.
  • Shares outstanding: 80,234,557 shares of common stock issued and outstanding as of September 30, 2026, per the condensed consolidated balance sheet.
  • Accumulated deficit: $489,303 thousand as of September 30, 2026, up from $356,567 thousand at December 31, 2025.

BridgeBio Oncology's Financial Position and Operating Results for the Quarter Ended September 30, 2026

BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT), a Delaware-incorporated clinical-stage oncology company headquartered in South San Francisco, California, reported a net loss of $34,176 thousand for the three months ended September 30, 2026, according to the filing. This compares to a net loss of $44,757 thousand for the three months ended September 30, 2025. For the nine-month period ended September 30, 2026, the company reported a net loss of $132,736 thousand, up from $95,247 thousand in the prior-year comparable period.

Total operating expenses for Q3 2026 were $37,488 thousand, consisting of $29,593 thousand in research and development expenses and $7,895 thousand in general and administrative expenses, the filing disclosed. For the nine months ended September 30, 2026, total operating expenses reached $143,854 thousand. The company reported total other income, net, of $3,312 thousand for Q3 2026, driven primarily by interest income of $3,262 thousand. Net loss per share attributable to common stockholders, basic and diluted, was $(0.43) for Q3 2026, based on a weighted-average share count of 80,184,540.

As of September 30, 2026, total assets stood at $346,224 thousand, with cash and cash equivalents of $76,479 thousand and combined short-term and long-term marketable securities of $238,852 thousand. Total liabilities were $52,836 thousand, and total stockholders' equity was $293,388 thousand. The accumulated deficit reached $489,303 thousand at the end of the quarter. The company reported accrued research and development liabilities of $32,681 thousand, up from $25,951 thousand at December 31, 2025, reflecting the company's ongoing clinical-stage development activities.

What Was Disclosed

BridgeBio Oncology Therapeutics, Inc. disclosed its unaudited condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, reporting increased cumulative losses, reduced cash balances, and continued spending on research and development programs.